Basit öğe kaydını göster

dc.contributor.authorHalis, Emre
dc.contributor.authorUlku, Sibel
dc.contributor.authorYalcintepe, Leman
dc.date.accessioned2021-03-03T15:18:48Z
dc.date.available2021-03-03T15:18:48Z
dc.date.issued2016
dc.identifier.citationYalcintepe L., Halis E., Ulku S., "Effect of CD38 on the multidrug resistance of human chronic myelogenous leukemia K562 cells to doxorubicin.", Oncology letters, cilt.11, sa.3, ss.2290-2296, 2016
dc.identifier.issn1792-1074
dc.identifier.othervv_1032021
dc.identifier.otherav_3e5272ea-0942-4906-8be1-e149dfe25df7
dc.identifier.urihttp://hdl.handle.net/20.500.12627/45761
dc.identifier.urihttps://doi.org/10.3892/ol.2016.4165
dc.description.abstractDrug resistance is a serious challenge in cancer chemotherapy. Alterations in the intracellular concentration and homeostasis of calcium (Ca2+) may contribute to the development of drug resistance. To investigate the mechanism of drug resistance in leukemia, the present study rendered human chronic myelogenous leukemia K562 cells resistant to the cytotoxic effect of doxorubicin by progressively adapting the sensitive parental K562 cells to doxorubicin. The resulting cells were termed K562/DOX. Subsequently, the expression of two multidrug resistance proteins, P-glycoprotein (P-gp) and multidrug resistance protein 1 (MRP1), was analyzed in K562/DOX cells. In addition to P-gp and MRP1, these cells also expressed cluster of differentiation (CD)38 and its active enzyme adenosine diphosphate (ADP)-ribosyl cyclase. The present study also demonstrated that K562/DOX cells responded to cyclic ADP-ribose-mediated increases in intracellular Ca2+. These data indicate that CD38 may participate in the development of drug resistance to doxorubicin in K562 cells.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectOnkoloji
dc.subjectİç Hastalıkları
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.titleEffect of CD38 on the multidrug resistance of human chronic myelogenous leukemia K562 cells to doxorubicin.
dc.typeMakale
dc.relation.journalOncology letters
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume11
dc.identifier.issue3
dc.identifier.startpage2290
dc.identifier.endpage2296
dc.contributor.firstauthorID230532


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster